ArticleInternational journal of ophthalmology2013
Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options.
Article in International journal of ophthalmology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis.Journal of perinatology : official journal of the California Perinatal Association · 2019Pooled it
- Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants.The Cochrane database of systematic reviews · 2018Pooled it
- Pooled it
- A randomized controlled clinical trial of the effect of supportive counseling on mental health in Iranian mothers of premature infants.BMC pregnancy and childbirth · 2021Trial
- Association of retinopathy of prematurity with early refractive development in mid-preterm infants.Eye (London, England) · 2026Article
- Efavirenz treatment improves retinal vaso-obliteration and pathological neovascularization in a mouse model of retinopathy of prematurity.Frontiers in medicine · 2026Article
- Inhibition of pathological angiogenesis in oxygen-induced retinopathy by arginine depletion with ADI-PEG20.Experimental eye research · 2026Article
- Incidence and treatment outcomes of retinopathy of prematurity in preterm infants assessed through wide-field fundus imaging: a retrospective cohort study.Translational pediatrics · 2025Article
- Effect of myeloid-derived suppressor cells on retinal epithelial cells in retinopathy of prematurity model.Translational pediatrics · 2025Article
- Investigation of the rates of retinopathy of prematurity and other diseases in infants born late preterm: is routine ROP examination required?Eye (London, England) · 2025Article
- Myeloid ACAT1/SOAT1: a novel regulator of dyslipidemia and retinal neovascularization.npj metabolic health and disease · 2025Review
- Clinical Approach and Anatomical Results in the Treatment of Retinopathy of Prematurity.The Eurasian journal of medicine · 2024Article
- A review on retinopathy of prematurity.Medical hypothesis, discovery & innovation ophthalmology journal · 2024Review
- Effects of fresh bone marrow mononuclear cell therapy in rat model of retinopathy of prematurity.Regenerative therapy · 2023Article
- Article
- Retinopathy of prematurity: from oxygen management to molecular manipulation.Molecular and cellular pediatrics · 2023Review
- Ocular Vascular Diseases: From Retinal Immune Privilege to Inflammation.International journal of molecular sciences · 2023Review
- Vascular cell-adhesion molecule 1 (VCAM-1) regulates JunB-mediated IL-8/CXCL1 expression and pathological neovascularization.Communications biology · 2023Article
- Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems.Pharmaceutics · 2023Review
- Twelve-year outcomes of bedside laser photocoagulation for severe retinopathy of prematurity.Frontiers in pediatrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinopathy of prematurity (ROP), a retinal vascular disease of premature infants, continues to be a major cause of preventable childhood blindness all over the world. The incidence of ROP varies among countries, being influenced by the quality of the level of neonatal intensive care. Here, we discuss the potential treatments that are now available or will soon or probably be available for ROP. Although ablation of the avascular retina with laser photocoagulation remains the current gold standard and well established therapy for ROP, some new therapeutic options including angiostatic therapies are being explored based on our knowledge of the pathophysiology of the ROP and complications and efficacy of laser treatment. However, prevention of the development of severe ROP and screening for ROP seem to be the best strategy in avoiding visual impairment caused by ROP in premature infants. New therapeutic interventions including vascular endothelial growth factor antibody administration, gene therapy and supplemental therapies should be supported with evidence-based data for the treatment of ROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.